AIDSVAX results: an answer, or just more questions?
Some time within the next few weeks, VaxGen is expected to announce the results of the Phase III trials of its first vaccine candidate based on a bivalent HIV envelope gp120, AIDSVAX B/B. Interpretation of these results will probably not be straightforward and will likely lead to many more unanswered questions. Following is a description of some of the key issues involved.
Johnston
Rowena
R
American Foundation for AIDS Research, New York, NY 10005-3902, USA. rowena.johnston@amfar.org
D016915:AIDS Vaccines; D017326:Clinical Trials, Phase III as Topic; D015699:HIV Envelope Protein gp120; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans; D016896:Treatment Outcome
D016915:AIDS Vaccines; C112734:AIDSVAX; D015699:HIV Envelope Protein gp120